An investment consortium completed the investment in Spirit Pharmaceuticals.

Private equity firms NewSpring Capital, Tecum Capital, Leedon Park Capital, and PNC Bank completed the investment in Spirit Pharmaceuticals, a developer and distributor of private label over-the-counter pharmaceutical products. Financial terms were not disclosed. “At NewSpring, we’re always looking to partner with high-performing, innovative management teams that are able to capitalise on new industry tailwinds. Having close partnerships with its customers and a growing desire among consumers for private label over-the-counter pharmaceutical products, Spirit Pharmaceuticals is poised for continued growth,” Anne Vazquez, NewSpring General Partner.